OMEGA-3-ACID ETHYL ESTERS capsule

OMEGA-3-ACID ETHYL ESTERS by

Drug Labeling and Warnings

OMEGA-3-ACID ETHYL ESTERS by is a Prescription medication manufactured, distributed, or labeled by KD Pharma USA, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Omega-3-acid ethyl esters is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg per dL) hypertriglyceridemia (HTG).

    Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters and should continue this diet during treatment with omega-3-acid ethyl esters.

    Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.

    Limitations of Use:

    The effect of omega-3-acid ethyl esters on the risk for pancreatitis has not been determined.

    The effect of omega-3-acid ethyl esters on cardiovascular mortality and morbidity has not been determined.

  • 2 DOSAGE AND ADMINISTRATION

    • Assess triglyceride levels carefully before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, medications) of high triglyceride levels and manage as appropriate [see Indications and Usage (1)].
    • Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters, and should continue this diet during treatment with omega-3-acid ethyl esters. In clinical studies, omega-3-acid ethyl esters was administered with meals.

    The daily dose of omega-3-acid ethyl esters is 4 grams per day. The daily dose may be taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily).

    Patients should be advised to swallow omega-3-acid ethyl esters whole. Do not break open, crush, dissolve, or chew omega-3-acid ethyl esters.

  • 3 DOSAGE FORMS AND STRENGTHS

    Omega-3-acid ethyl esters, USP are supplied as 1-gram oblong, transparent soft gelatin capsules filled with light yellowish oil printed with "O3" in white ink across one side.

  • 4 CONTRAINDICATIONS

    Omega-3-acid ethyl esters are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters or any of its components.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Monitoring: Laboratory Tests

    In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with omega-3-acid ethyl esters. In some patients, increases in ALT levels without a concurrent increase in AST levels were observed.

    In some patients, omega-3-acid ethyl esters increases LDL-C levels. LDL-C levels should be monitored periodically during therapy with omega-3-acid ethyl esters.

    Laboratory studies should be performed periodically to measure the patient's TG levels during therapy with omega-3-acid ethyl esters.

    5.2 Fish Allergy

    Omega-3-acid ethyl esters contain ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources. It is not known whether patients with allergies to fish and/or shellfish, are at increased risk of an allergic reaction to omega-3-acid ethyl esters. Omega-3-acid ethyl esters should be used with caution in patients with known hypersensitivity to fish and/or shellfish.

    5.3 Recurrent Atrial Fibrillation (AF) or Flutter

    In a double-blind, placebo-controlled trial of 663 subjects with symptomatic paroxysmal AF (n = 542) or persistent AF (n = 121), recurrent AF or flutter was observed in subjects randomized to omega-3-acid ethyl esters who received 8 grams per day for 7 days and 4 grams per day thereafter for 23 weeks at a higher rate relative to placebo. Subjects in this trial had median baseline triglycerides of 127 mg per dL, had no substantial structural heart disease, were taking no anti-arrhythmic therapy (rate control permitted), and were in normal sinus rhythm at baseline.

    At 24 weeks, in the paroxysmal AF stratum, there were 129 (47%) first recurrent symptomatic AF or flutter events on placebo and 141 (53%) on omega-3-acid ethyl esters [primary endpoint, HR 1.19; 95% CI: 0.93, 1.35]. In the persistent AF stratum, there were 19 (35%) events on placebo and 34 (52%) events on omega-3-acid ethyl esters [HR 1.63; 95% CI: 0.91, 2.18]. For both strata combined, the HR was 1.25; 95% CI: 1.00, 1.40. Although the clinical significance of these results is uncertain, there is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first 2 to 3 months of initiating therapy.

    Omega-3-acid ethyl esters are not indicated for the treatment of AF or flutter.

  • 6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Adverse reactions reported in at least 3% and at a greater rate than placebo for subjects treated with omega-3-acid ethyl esters based on pooled data across 23 clinical trials are listed in Table 1.

    Adverse Reaction*Omega-3-acid ethyl esters
    (n = 655)
    Placebo (n = 370)
    n%n%
  • * Trials included subjects with HTG and severe HTG.
  • Eructation29451
    Dyspepsia22362
    Taste perversion2741<1

    Additional adverse reactions from clinical trials are listed below:

    Digestive System

    Constipation, gastrointestinal disorder and vomiting.

    Metabolic and Nutritional Disorders

    Increased ALT and increased AST.

    Skin

    Pruritus and rash.

    6.2 Postmarketing Experience

    In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of omega-3-acid ethyl esters. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.

    The following events have been reported: anaphylactic reaction, hemorrhagic diathesis, urticaria.

  • 7 DRUG INTERACTIONS

    7.1 Anticoagulants or Other Drugs Affecting Coagulation

    Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is unknown whether omega-3-acid ethyl esters can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.Omega-3-acid ethyl esters should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.

    Animal Data

    Omega-3-acid ethyl esters have been shown to have an embryocidal effect in pregnant rats when given in doses resulting in exposures 7 times the recommended human dose of 4 grams per day based on a body surface area comparison.

    In female rats given oral gavage doses of 100, 600, and 2,000 mg per kg per day beginning 2 weeks prior to mating and continuing through gestation and lactation, no adverse effects were observed in the high-dose group (5 times human systemic exposure following an oral dose of 4 grams per day based on body surface area comparison).

    In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg per kg per day from gestation Day 6 through 15, no adverse effects were observed (14 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

    In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg per kg per day from gestation Day 14 through lactation Day 21, no adverse effects were seen at 2,000 mg per kg per day (5 times the human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison). However, decreased live births (20% reduction) and decreased survival to postnatal Day 4 (40% reduction) were observed in a dose-ranging study using higher doses of 3,000 mg per kg per day (7 times the human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

    In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg per kg per day from gestation Day 7 through 19, no findings were observed in the fetuses in groups given 375 mg per kg per day (2 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison). However, at higher doses, evidence of maternal toxicity was observed (4 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

    8.3 Nursing Mothers

    Studies with omega-3-acid ethyl esters have demonstrated excretion in human milk. The effect of this excretion on the infant of a nursing mother is unknown; caution should be exercised when omega-3-acid ethyl esters are administered to a nursing mother. An animal study in lactating rats given oral gavage 14C-ethyl EPA demonstrated that drug levels were 6 to 14 times higher in milk than in plasma.

    8.4 Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

    8.5 Geriatric Use

    A limited number of subjects older than 65 years were enrolled in the clinical trials of omega-3-acid ethyl esters. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.

  • 9 DRUG ABUSE AND DEPENDENCE

    Omega-3-acid ethyl esters do not have any known drug abuse or withdrawal effects.

  • 11 DESCRIPTION

    Omega-3-acid ethyl esters, USP, lipid-regulating agents, are supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of omega-3-acid ethyl esters, USP contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA — approximately 465 mg) and docosahexaenoic acid (DHA — approximately 375 mg).

    The empirical formula of EPA ethyl ester is C22H34O2, and the molecular weight of EPA ethyl ester is 330.51. The structural formula of EPA ethyl ester is:

    Chemical Structure

    The empirical formula of DHA ethyl ester is C24H36O2, and the molecular weight of DHA ethyl ester is 356.55. The structural formula of DHA ethyl ester is:

    Chemical Structure

    Omega-3-acid ethyl esters, USP also contain the following inactive ingredients: gelatin, glycerol, and purified water.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of omega-3-acid ethyl esters is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-acid ethyl esters may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.

    12.3 Pharmacokinetics

    Absorption

    In healthy volunteers and in subjects with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters (omega-3-acid ethyl esters) induced dose dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters.

    Specific Populations

    Age: Uptake of EPA and DHA into serum phospholipids in subjects treated with omega-3-acid ethyl esters was independent of age (younger than 49 years versus 49 years and older).

    Male and Female Patients: Females tended to have more uptake of EPA into serum phospholipids than males. The clinical significance of this is unknown.

    Pediatric Patients: Pharmacokinetics of omega-3-acid ethyl esters have not been studied.

    Patients with Renal or Hepatic Impairment: Omega-3-acid ethyl esters has not been studied in patients with renal or hepatic impairment.

    Drug Interaction Studies

    Simvastatin: In a 14-day trial of 24 healthy adult subjects, daily coadministration of simvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect the extent (AUC) or rate (Cmax) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin, at steady state.

    Atorvastatin: In a 14-day trial of 50 healthy adult subjects, daily coadministration of atorvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or Cmax of exposure to atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady state.

    Rosuvastatin: In a 14-day trial of 48 healthy adult subjects, daily coadministration of rosuvastatin 40 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or Cmax of exposure to rosuvastatin at steady state.

    In vitro studies using human liver microsomes indicated that clinically significant cytochrome P450-mediated inhibition by EPA/DHA combinations are not expected in humans.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis , Mutagenesis , Impairment of Fertility

    In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg per kg per day, males were treated with omega-3-acid ethyl esters for 101 weeks and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 grams per day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice.

    Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without metabolic activation in the bacterial mutagenesis (Ames) test with Salmonella typhimurium and Escherichia coli or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Omega-3-acid ethyl esters were negative in the in vivo mouse micronucleus assay.

    In a rat fertility study with oral gavage doses of 100, 600, and 2,000 mg per kg per day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to and throughout mating, gestation, and lactation. No adverse effect on fertility was observed at 2,000 mg per kg per day (5 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

  • 14 CLINICAL STUDIES

    14.1 Severe Hypertriglyceridemia

    The effects of omega-3-acid ethyl esters 4 grams per day were assessed in 2 randomized, placebo-controlled, doubleblind, parallel-group trials of 84 adult subjects (42 on omega-3-acid ethyl esters, 42 on placebo) with very high triglyceride levels. Subjects whose baseline triglyceride levels were between 500 and 2,000 mg per dL were enrolled in these 2 trials of 6 and 16 weeks' duration. The median triglyceride and LDL-C levels in these subjects were 792 mg per dL and 100 mg per dL, respectively. Median HDL-C level was 23.0 mg per dL.

    The changes in the major lipoprotein lipid parameters for the groups receiving omega-3-acid ethyl esters or placebo are shown in Table 2.

    Table 2. Median Baseline and Percent Change from Baseline in Lipid Parameters in Subjects with Severe Hypertriglyceridemia (≥500 mg per dL)
    ParameterOmega-3-acid ethyl esters
    n=42
    Placebo
    n=42
    Difference
    BL% ChangeBL% Change
    BL = Baseline (mg per dL); % Change = Median Percent Change from Baseline; Difference = Omega-3-acid ethyl esters Median % Change – Placebo Median % Change.
    TG816-44.9788+6.7-51.6
    Non-HDL-C271-13.8292-3.6-10.2
    TC296-9.7314-1.7-8.0
    VLDL-C175-41.7175-0.9-40.8
    HDL-C22+9.1240.0+9.1
    LDL-C89+44.5108-4.8+49.3

    Omega-3-acid ethyl esters 4 grams per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with omega-3-acid ethyl esters to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively.

    The effect of omega-3-acid ethyl esters on the risk of pancreatitis has not been determined.

    The effect of omega-3-acid ethyl esters on cardiovascular mortality and morbidity has not been determined.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Omega-3-acid ethyl esters, USP are supplied as 1-gram oblong, transparent soft gelatin capsules filled with light yellowish oil printed with "O3" in white ink across one side.

    Bottles of 120: NDC: 72998-850-12

    Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Do not freeze. Keep out of reach of children.

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information).

    Information for Patients:

    • Omega-3-acid ethyl esters should be used with caution in patients with known sensitivity or allergy to fish and/or shellfish [see Warnings and Precautions (5.2)].
    • Advise patients that use of lipid-regulating agents does not reduce the importance of adhering to diet [see Dosage and Administration (2)].
    • Advise patients not to alter omega-3-acid ethyl esters in any way and to ingest intact capsules only [see Dosage and Administration (2)].
    • Instruct patients to take omega-3-acid ethyl esters as prescribed. If a dose is missed, advise patients to take it as soon as they remember. However, if they miss one day of omega-3-acid ethyl esters, they should not double the dose when they take it.
  • SPL UNCLASSIFIED SECTION

    Manufactured for:

    KD Pharma USA Inc.
    14193 SW 119th Avenue, Suite 201
    Miami, Florida 33186
    USA

    Revised: October 2020
    Revision: 1

  • PATIENT INFORMATION

    OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP
    (oh may' ga as' id eth' il es' ters).

    What are OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP?

    OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP are a prescription medicine used along with a low-fat and low-cholesterol diet to lower very high triglyceride (fat) levels in adults.

    It is not known if OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP change your risk of having inflammation of your pancreas (pancreatitis).

    It is not known if OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP prevent you from having a heart attack or stroke.

    It is not known if OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP are safe and effective in children.

    Who should not take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP?

    Do not take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP if you are allergic to omega-3-acid ethyl esters or any of the ingredients in OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP. See the end of this leaflet for a complete list of ingredients in OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.

    Before taking OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP, tell your healthcare provider about all of your medical conditions, including if you:

    • have diabetes.
    • have a low thyroid problem (hypothyroidism).
    • have a liver problem.
    • have a pancreas problem.
    • have a certain heart rhythm problem called atrial fibrillation or flutter.
    • are allergic to fish or shellfish. It is not known if people who are allergic to fish or shellfish are also allergic to OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.
    • are pregnant or plan to become pregnant. It is not known if OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.

    Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP can interact with certain other medicines that you are taking. Using OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP with medicines that affect blood clotting (anticoagulants or blood thinners) may cause serious side effects.

    How should I take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP?

    • Take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP exactly as your healthcare provider tells you to take them.
    • You should not take more than 4 capsules of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP each day. Either take all 4 capsules at one time or 2 capsules two times a day.
    • Do not change your dose or stop OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP without talking to your healthcare provider.
    • Take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP with food.
    • Take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP whole. Do not break, open, crush, dissolve, or chew OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP before swallowing. If you cannot swallow OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP whole, tell your healthcare provider. You may need a different medicine.
    • If you miss a dose of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP, take the missed dose as soon as you remember. If you miss one day of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP, do not double your dose the next time you take it.
    • Your healthcare provider may start you on a cholesterol-lowering diet before giving you OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP. Stay on this diet while taking OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.
    • Your healthcare provider should do blood tests to check your triglyceride, bad cholesterol (LDL-C) and liver function (ALT and AST) levels while you take OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.

    What are the possible side effects of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP?

    OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP may cause serious side effects, including:

    • changes in certain blood tests. OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP may cause an increase in the results of blood tests used to check your liver function and your bad cholesterol levels.
    • increased risk of a heart rhythm problem in people who have a heart rhythm problem. OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP may cause an increase in the frequency of a heart rhythm problem (atrial fibrillation or flutter), especially if the first few months of taking OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP, if you already have a heart rhythm problem.

    The most common side effects of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP include:

    • burping
    • upset stomach
    • a change in your sense of taste

    These are not all the possible side effects of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    How should I store OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP?

    • Store OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP at room temperature between 68°F to 77°F (20°C to 25°C).
    • Do not freeze OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP.
    • Safely throw away medicine that is out of date or no longer needed.

    Keep OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP and all medicines out of the reach of children.

    General information about the safe and effective use of OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP

    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP for a condition for which it was not prescribed. Do not give OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP to other people, even if they have the same symptoms you have. It may harm them.

    You can ask your healthcare provider or pharmacist for information about OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP that is written for health professionals.

    What are the ingredients in OMEGA-3-ACID ETHYL ESTERS CAPSULES, USP?

    Active Ingredient: omega-3-acid ethyl esters, mostly EPA and DHA
    Inactive Ingredients: gelatin, glycerol, and purified water.

    Manufactured for:
    KD Pharma USA Inc.
    14193 SW 119th Avenue, Suite 201
    Miami, Florida 33186
    USA

    This patient labeling has been approved by the U.S. Food and Drug Administration.

    Revised: October 2020
    Revision: 1

  • PRINCIPAL DISPLAY PANEL - 120 Capsule Bottle Label

    NDC: 72998-850-12

    Omega-3-Acid
    Ethyl Esters
    Capsules, USP

    1 gram*

    Swallow capsules whole.

    Rx Only

    120 Capsules

    KD Pharma™

    PRINCIPAL DISPLAY PANEL - 120 Capsule Bottle Label
  • INGREDIENTS AND APPEARANCE
    OMEGA-3-ACID ETHYL ESTERS 
    omega-3-acid ethyl esters capsule
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 72998-850
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    OMEGA-3-ACID ETHYL ESTERS (UNII: D87YGH4Z0Q) (OMEGA-3 FATTY ACIDS - UNII:71M78END5S) OMEGA-3-ACID ETHYL ESTERS1 g
    Inactive Ingredients
    Ingredient NameStrength
    .ALPHA.-TOCOPHEROL (UNII: H4N855PNZ1)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    WATER (UNII: 059QF0KO0R)  
    Product Characteristics
    ColorWHITE (Translucent) Scoreno score
    ShapeCAPSULE (Oblong) Size25mm
    FlavorImprint Code O3
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 72998-850-12120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product05/01/2021
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21250405/01/2021
    Labeler - KD Pharma USA, Inc. (081493324)

  • © 2021 FDA.report
    This site is not affiliated with or endorsed by the FDA.